Enterprise Value

4.161B

Cash

305.7M

Avg Qtr Burn

-20.14M

Short % of Float

8.12%

Insider Ownership

4.65%

Institutional Own.

99.47%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Povetacicept (ALPN-303) Details
Autoimmune disease, Immune complex membranoproliferative glomerulonephritis, Autoimmune nephritis, IgA nephropathy

Phase 3

Initiation

Acazicolcept (ALPN-101) Details
Systemic lupus erythematosus

Phase 2

Data readout

Povetacicept (ALPN-303) Details
Autoimmune disease, Systemic lupus erythematosus

Phase 2

Initiation

Povetacicept (ALPN-303) Details
Autoimmune disease, Primary immune thrombocytopenia

Phase 1b

Data readout

Failed

Discontinued